Page 21 - Read Online

Page 12 of 12 Hiyama et al. Hepatoma Res 2021;7:44 https://dx.doi.org/10.20517/2394-5079.2021.21

children. Front Biosci (Elite Ed) 2012;4:1293-302. DOI PubMed
15. Okur MH, Yankol Y, Cimşit B, et al. Liver Transplant in Children with Hepatoblastoma. Exp Clin Transplant 2019;17:644-7. DOI
PubMed
16. Aronson DC, Weeda VB, Maibach R, et al; Childhood Liver Tumour Strategy Group (SIOPEL). Microscopically positive resection
margin after hepatoblastoma resection: what is the impact on prognosis? Eur J Cancer 2019;106:126-32. DOI PubMed
17. Hafberg E, Borinstein SC, Alexopoulos SP. Contemporary management of hepatoblastoma. Curr Opin Organ Transplant
2019;24:113-7. DOI PubMed
18. Ren X, Li H, Diao M, Xu H, Li L. Impact of microscopically margin-positive resection on survival in children with hepatoblastoma
after hepatectomy: a retrospective cohort study. Int J Clin Oncol 2020;25:765-73. DOI PubMed
19. Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver
Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 2011;27:1-8. DOI PubMed
20. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma - results from the
International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer 2000;36:1418-25. DOI PubMed
21. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 2000;1:94-
100. DOI PubMed
22. Roebuck DJ, Aronson D, Clapuyt P, et al; International Childrhood Liver Tumor Strategy Group. 2005 PRETEXT: a revised staging
system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 2007;37:123-32; quiz 249.
DOI PubMed PMC
23. López-Terrada D, Alaggio R, de Dávila MT, et al; Children's Oncology Group Liver Tumor Committee. Towards an international
pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol
2014;27:472-91. DOI PubMed
24. Hiyama E, Ueda Y, Onitake Y, et al; Japanese Study Group for Pediatric Liver Tumor. A cisplatin plus pirarubicin-based JPLT2
chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT). Pediatr Surg
Int 2013;29:1071-5. DOI PubMed
25. Nishimura S, Sato T, Fujita N, et al. High-dose chemotherapy in children with metastatic hepatoblastoma. Pediatr Int 2002;44:300-5.
DOI PubMed
26. Karski EE, Dvorak CC, Leung W, et al. Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric
blood and marrow transplant consortium experience and review of the literature. J Pediatr Hematol Oncol 2014;36:362-8. DOI
PubMed
27. Zsíros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent
chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010;28:2584-90. DOI PubMed
28. Katzenstein HM, Furman WL, Malogolowkin MH, et al. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma:
A report from the Children's Oncology Group AHEP0731 study committee. Cancer 2017;123:2360-7. DOI PubMed PMC
29. Sasaki F, Matsunaga T, Iwafuchi M, et al; (Japanese Study Group for Pediatric Liver Tumor). Outcome of hepatoblastoma treated with
the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver
Tumor. J Pediatr Surg 2002;37:851-6. DOI PubMed
30. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous
infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology
Group. J Clin Oncol 2000;18:2665-75. DOI PubMed
31. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful
approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000;18:3819-28. DOI
PubMed
32. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med
2009;361:1662-70. DOI PubMed